Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun 130000, China.
Clinical Research Big Data Center, Jilin Cancer Hospital, Changchun 130000, China.
Future Oncol. 2023 Jun;19(18):1303-1314. doi: 10.2217/fon-2022-0523. Epub 2023 Jun 5.
The role of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in limited-stage small-cell lung cancer (LS-SCLC) remains controversial. Using pooled hazard ratios (HR) with 95% CIs, we assessed the correlation of pre-treatment NLR and PLR with overall survival (OS) and progression-free survival (PFS) in LS-SCLC. Publication bias was assessed by Begg's and Egger's tests. Ten studies were enrolled in our meta-analysis. Pooled analyses showed that pre-treatment high NLR was significantly associated with poor OS (HR: 1.80) and PFS (HR: 1.69) in LS-SCLC patients. High pre-treatment PLR was also associated with shorter OS (HR: 1.52) and PFS (HR: 1.39) in LS-SCLC patients. Our meta-analysis suggests that high pre-treatment NLR or PLR may be negatively related to OS and PFS in LS-SCLC.
中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）作为局限期小细胞肺癌（LS-SCLC）的预后标志物的作用仍存在争议。我们使用合并危险比（HR）及其 95%置信区间（CI）评估了 LS-SCLC 患者治疗前 NLR 和 PLR 与总生存期（OS）和无进展生存期（PFS）的相关性。通过 Begg 和 Egger 检验评估发表偏倚。我们的荟萃分析纳入了 10 项研究。合并分析表明，LS-SCLC 患者治疗前高 NLR 与 OS（HR：1.80）和 PFS（HR：1.69）不良显著相关。高 PLR 也与 LS-SCLC 患者的 OS（HR：1.52）和 PFS（HR：1.39）较短有关。我们的荟萃分析表明，LS-SCLC 患者治疗前高 NLR 或 PLR 可能与 OS 和 PFS 呈负相关。
